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blood aqueous barrier (BAB) following cataract surgery in uncomplicated eyes. Twenty patients [10 male, mean age 71-4 (SD 12.7) years] admitted for routine cataract surgery were randomised into two groups. All patients recruited into the study were free of other ocular disease and were not taking any anti-inflammatory medication. Group A received a subconjunctival injection of cefuroxime (125 mg) alone while group B received a subconjunctival injection of both cefuroxime and Betnesol. All surgery was performed by a single surgeon using a standardised surgical technique and all patients received the same postoperative medication. The Kowa laser flare cell meter was used to measure aqueous flare and cells preoperatively and on the first, second, and seventh postoperative day, and at 1 and 3 months following surgery. The code was broken only after all patients had been followed-up for 3 months postoperatively. There was no significant difference between the two groups in aqueous flare and cells at any of the postoperative visits. In this study we were unable to demonstrate any beneficial effect of subconjunctival betamethasone on damage to Scans in which the difference between BG1 and BG2 exceeded 15% (indicative of a nonuniform background) were excluded and the scan repeated. To prevent 'massaging' of data, once the instrument had been aligned each sequential scan was accepted provided the difference between the background counts was less than 15%. The results of five scans were then averaged. Laser flare cell measurements were performed preoperatively, and on the first, second, and seventh postoperative day and at 1 and 3 months following surgery.
SUBJECTS
Informed consent was obtained from all patients prior to the study. Twenty patients admitted to St Thomas' Hospital for routine cataract surgery were recruited for the study. All patients entered into the study were free of other ocular disease and were not taking any anti-inflammatory medication. Patients with systemic diseases known to affect the BAB (for example, diabetes) were also excluded from the study. The patients were then randomised on a double-blind basis into two groups (groups A and B). Patients in group A were allocated to receive a subconjunctival injection of cefuroxime 125 mg alone while patients in group B were to receive a subconjunctival injection of both cefuroxime 125 mg and Betnesol (4 mg). The basis of allocation was known only to the surgeon, the code being broken after a 3 month follow-up had been completed on all patients. The surgeon was not involved in the postoperative assessment of the patients.
SURGERY
All surgery was performed by the same surgeon (JDM) using a standardised extracapsular surgical technique. At the completion of the procedure the surgeon was given the patient's code (group A or B) and the appropriate subconjunctival injection administered. Subconjunctival injections were administered transconjunctivally into the inferotemporal fornix. Postoperatively all patients received the same medication consisting of topical Maxitrol (dexamethasone 0-1% and neomycin 0 35%) four times daily for the first week and twice daily for a further 3 weeks.
STATISTICAL ANALYSIS
Differences between the two groups in the Figure 1 . There was a peak in aqueous flare and cells on the first postoperative day, followed by a rapid decline in the first week, with a more gradual return to normal levels by 3 months following surgery. There was no significant difference (p>0 05) between the two groups in both flare and cells at any of the postoperative visits. On the first postoperative day there was also no difference between the two groups in the number of eyes subconjunctival betamethasone.) (three eyes in each group) with marked anterior chamber inflammation (flare values above 150 photons/ms). There were no cases of postoperative iritis in either group requiring a change in the standard topical medication regimen.
Discussion
In this preliminary study we have shown that subconjunctival betamethasone has no beneficial effect on damage to the BAB (as measured by the laser flare cell meter) following cataract surgery in uncomplicated eyes. In view of the proved effect of topical steroids given later on in the postoperative period, the most likely reason for this finding is that the effect of subconjunctival Betnesol is short lived and complete within too short a time to influence the later inflammatory consequences of surgery.
Most of the published reports on the kinetics ofsubconjunctival injections are based on animal studies. Maurice and Otal found that following a subconjunctival injection of small volumes of tracers (22Na, '3'I-hippurate, albumin) in the rabbit eye there was rapid loss of the tracer from the subconjunctival space into the blood. The half-life varied from 9 minutes for "Na and 20 minutes for '1I-hippurate to 9 hours for albumin. After 1 hour "Na was no longer detectable at the injection site and there was little penetration of tracer into the anterior chamber. In the case of "2Na the peak concentration in the aqueous occurred within the first hour, and was only 1% of the total injected dose. With the larger molecules the peak concentration occurred later and also at a lower percentage of total dose. They concluded that penetration into the aqueous was only possible for a briefperiod after injection due to the rapid clearance of tracer from the injection site into blood. Wine et al,6 also using the rabbit, investigated the time course and route of ocular penetration of radio-labelled '4C hydrocortisone from a subconjunctival injection (0 25 ml of a 2-5% solution). They found that a peak ocular concentration of hydrocortisone (176-7 ,ug) occurred within 30 minutes of injection with a rapid decline in concentration within 2 hours (41p1 rIg) and a more gradual decline to 1 8 [ig at 72 hours. If the technique of subconjunctival injection was,modified so that the conjunctival surface remained intact the peak concentration was significantly reduced (3-9 ,ug). They concluded that the major route of ocular penetration from a subconjunctival injection of hydrocortisone was therefore by leakage through the needle puncture wound into the conjunctival sac and then through the cornea to the anterior chamber by the tear film. However autoradiographic studies in rabbit eyes do indicate that subconjunctival hydrocortisone can penetrate directly through the sclera from the injection depot site. McCartney et a17 found that penetration occurred within 30 minutes in the inflamed eye and only after 4 hours in the normal eye. They also confirmed that only a very small proportion ofthe drug penetrated into the eye (about 1-2%).
It has been assumed in most of the animal studies on this subject that the results are relevant and applicable to humans. However Maurice This would be consistent with clinical studies in which postoperative iritis and particularly fibrinous iritis is reported to occur usually 3-5 days after surgery. 10 II The absorption of subconjunctival steroids and their therapeutic effect is also affected by the type of steroid used and the vehicle used to deliver it. Betamethasone and dexamethasone have 5-7 times greater systemic antiinflammatory activity than prednisolone on a weight for weight basis. The absorption of these steroids into aqueous following topical application has been shown to be significantly different depending on the vehicle used. McGhee et al 2 measured the aqueous concentrations (using gas chromatography with mass spectrometry (GCMS)) of prednisolone acetate (1%), fluoromethalone alcohol (0 1%), dexamethasone alcohol (0-1%), betamethasone sodium phosphate (0 1%), and prednisolone sodium phosphate (0 5%) following single drop instillation. They found a large variation in peak aqueous concentration, ranging from 669-6 ng/ml with prednisolone acetate, 31-0 ng/ml with dexamethasone alcohol, 25 6 ng/ml with prednisolone sodium phosphate, and 7-7 ng/ml with betamethasone sodium phosphate. Acetate 
